Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 1
1998 2
1999 5
2000 5
2001 2
2002 3
2003 2
2004 2
2005 10
2006 2
2008 3
2009 3
2010 5
2011 4
2012 5
2013 2
2014 3
2015 3
2016 4
2017 7
2018 6
2019 4
2020 7
2021 10
2022 2
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G. Ost P, et al. Among authors: goetghebeur e. J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14. J Clin Oncol. 2018. PMID: 29240541 Clinical Trial.
Editorial.
Day S, Goetghebeur E, Greenhouse J, Platt R. Day S, et al. Among authors: goetghebeur e. Stat Med. 2021 Jan 15;40(1):1-2. doi: 10.1002/sim.8864. Stat Med. 2021. PMID: 33368370 No abstract available.
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.
Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A, Semac I, Vanhoutte F, Goetghebeur E, Reynders D, Ost P. Zilli T, et al. Among authors: goetghebeur e. Eur Urol Focus. 2021 Mar;7(2):241-244. doi: 10.1016/j.euf.2020.12.010. Epub 2020 Dec 29. Eur Urol Focus. 2021. PMID: 33386290 Free article. Clinical Trial.
Editorial.
Day S, Goetghebeur E, Greenhouse J. Day S, et al. Among authors: goetghebeur e. Stat Med. 2020 Feb 28;39(5):515-516. doi: 10.1002/sim.8480. Stat Med. 2020. PMID: 32056263 No abstract available.
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
Spaas M, Sundahl N, Kruse V, Rottey S, De Maeseneer D, Duprez F, Lievens Y, Surmont V, Brochez L, Reynders D, Danckaert W, Goetghebeur E, Van den Begin R, Van Gestel D, Renard V, Dirix P, Ost P. Spaas M, et al. Among authors: goetghebeur e. JAMA Oncol. 2023 Sep 1;9(9):1205-1213. doi: 10.1001/jamaoncol.2023.2132. JAMA Oncol. 2023. PMID: 37410476 Clinical Trial.
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures.
Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J, Cislo P, Coens C, Dirven L, Speck RM, Fitzgerald K, Galinsky J, Giesinger JM, Holzner B, Le Cessie S, O'Connor D, Oliver K, Pawar V, Quinten C, Schlichting M, Ren J, Roychoudhury S, Taphoorn MJB, Velikova G, Wintner LM, Griebsch I, Bottomley A; SISAQOL-IMI Consortium. Pe M, et al. Lancet Oncol. 2023 Jun;24(6):e270-e283. doi: 10.1016/S1470-2045(23)00157-2. Lancet Oncol. 2023. PMID: 37269858 Free article. Review.
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice.
Liu L, Choi J, Musoro JZ, Sauerbrei W, Amdal CD, Alanya A, Barbachano Y, Cappelleri JC, Falk RS, Fiero MH, Regnault A, Reijneveld JC, Sandin R, Thomassen D, Roychoudhury S, Goetghebeur E, le Cessie S; SISAQOL-IMI Work Package 3. Liu L, et al. Among authors: goetghebeur e. Lancet Oncol. 2023 May;24(5):e197-e206. doi: 10.1016/S1470-2045(23)00110-9. Lancet Oncol. 2023. PMID: 37142381 Review.
Beyond intention to treat.
Goetghebeur E, Loeys T. Goetghebeur E, et al. Epidemiol Rev. 2002;24(1):85-90. doi: 10.1093/epirev/24.1.85. Epidemiol Rev. 2002. PMID: 12119861 Review. No abstract available.
Analysing compliance in clinical trials.
Dunn G, Goetghebeur E. Dunn G, et al. Among authors: goetghebeur e. Stat Methods Med Res. 2005 Aug;14(4):325-6. doi: 10.1191/0962280205sm402ed. Stat Methods Med Res. 2005. PMID: 16178135 No abstract available.
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Trøseid M, et al. Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8. Crit Care. 2023. PMID: 36627655 Free PMC article. Clinical Trial.
99 results